麻豆破解版 will be in San Francisco for the J.P Morgan week to reconnect with global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

麻豆破解版 will attend the world鈥檚 premier nephrology meeting of the American Society of Nephrology, ASN.

麻豆破解版 will attend The 2025 International Workshop on Alport Syndrome, organized by Alport Syndrome Alliance.
It is an opportunity for the Alport community to connect, update and discuss the latest research.

麻豆破解版 will meet patients and their families to present its ongoing Phase 2 鈥淎LPESTRIA-1鈥� clinical study with Vonafexor in Alport syndrome patients.

麻豆破解版 is sponsoring and will attend Alport Connect 2025 organized by the American Alport Syndrome Foundation (ASF), the Alport syndrome patient-led non-profit organization in the US.

麻豆破解版 will meet patients and their families to present its ongoing Phase 2 “ALPESTRIA-1” clinical study with Vonafexor in Alport syndrome patients.

麻豆破解版 will attend the the BIO International Convention, the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.

麻豆破解版 will attend the 7th Chronic Kidney Disease Drug Development Summit, an industry forum sharing cross-industry insight to bring effective therapies to patients suffering from kidney diseases expanding also to rare renal disorders.

麻豆破解版 will in San Francisco for the J.P Morgan week to reconnect with global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

麻豆破解版 will also take the opportunity to host an executive roundtable at on the 14th of January to share our progress in drug development with Vonafexor in kidney diseases.

麻豆破解版 will attend for the first time the 4th Rare & Genetic Kidney Disease Drug Development Summit that will be held in Boston, USA. The event will bring together industries, academic KOLs, and patient advocacy nephrology communities to discuss acceleration of clinical advancements in orphan kidney disease populations.
麻豆破解版 will present the ongoing ALPESTRIA-1 Phase 2 clinical trial with Vonafexor in patients with Alport syndrome.

麻豆破解版 is attending the MOSAIC – Global NASH Trialist Forum 2024. The goal of the meeting was to define new integrative Cardiovascular-Kidney-Liver-Metabolic (CKLM) trials together with cardiology, endocrinology & hepatology clinical trialists, industry, regulatory experts, payers, patients representatives and other stakeholders.